EDITAS MEDICINE, INC. Deferred Revenue (Non-Current)
EDITAS MEDICINE, INC. (EDIT) had Deferred Revenue (Non-Current) of $94.72 million as of 2017-12-31, per its 10-K filed 2018-03-08.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:DeferredRevenueNoncurrent · last filed 2018-03-08
- 2017-12-31: Deferred Revenue, Noncurrent $94.72M.
- 2017-09-30: Deferred Revenue, Noncurrent $97.85M.
- 2017-06-30: Deferred Revenue, Noncurrent $100.95M.
- 2017-03-31: Deferred Revenue, Noncurrent $104.03M.
| Period end | Deferred Revenue, Noncurrent |
|---|---|
| 2017-12-31 | $94.72M 10-K · filed 2018-03-08 |
| 2017-09-30 | $97.85M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $100.95M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $104.03M 10-Q · filed 2017-05-15 |
| 2016-12-31 | $26.00M 10-K · filed 2018-03-08 |
| 2016-09-30 | $25.80M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $25.64M 10-Q · filed 2016-08-10 |
| 2016-03-31 | $25.48M 10-Q · filed 2016-05-13 |
| 2015-12-31 | $25.32M 10-K · filed 2017-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |